Abstract
OBJECTIVES: Identification of children with sepsis-associated multiple organ dysfunction syndrome (MODS) at risk for poor outcomes remains a challenge. We sought to the determine reproducibility of the data-driven "persistent hypoxemia, encephalopathy, and shock" (PHES) phenotype and determine its association with inflammatory and endothelial biomarkers, as well as biomarker-based pediatric risk strata. DESIGN: We retrained and validated a random forest classifier using organ dysfunction subscores in the 2012-2018 electronic health record (EHR) dataset used to derive the PHES phenotype. We used this classifier to assign phenotype membership in a test set consisting of prospectively (2003-2023) enrolled pediatric septic shock patients. We compared profiles of the PERSEVERE family of biomarkers among those with and without the PHES phenotype and determined the association with established biomarker-based mortality and MODS risk strata. SETTING: Twenty-five PICUs across the United States. PATIENTS: EHR data from 15,246 critically ill patients with sepsis-associated MODS split into derivation and validation sets and 1,270 pediatric septic shock patients in the test set of whom 615 had complete biomarker data. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The area under the receiver operator characteristic curve of the modified classifier to predict PHES phenotype membership was 0.91 (95% CI, 0.90-0.92) in the EHR validation set. In the test set, PHES phenotype membership was associated with both increased adjusted odds of complicated course (adjusted odds ratio [aOR] 4.1; 95% CI, 3.2-5.4) and 28-day mortality (aOR of 4.8; 95% CI, 3.11-7.25) after controlling for age, severity of illness, and immunocompromised status. Patients belonging to the PHES phenotype were characterized by greater degree of systemic inflammation and endothelial activation, and were more likely to be stratified as high risk based on PERSEVERE biomarkers predictive of death and persistent MODS. CONCLUSIONS: The PHES trajectory-based phenotype is reproducible, independently associated with poor clinical outcomes, and overlapped with higher risk strata based on prospectively validated biomarker approaches.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 512-517 |
| Number of pages | 6 |
| Journal | Pediatric Critical Care Medicine |
| Volume | 25 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2024 |
Funding
This work was supported by grant R21HD096402 from the Eunice Kennedy Shriver National Institute for Child Health and Human Development (Dr. Sanchez-Pinto). Drs. Atreya and Sanchez-Pinto received funding from R21GM151703. Cincinnati Children's Hospital Medical Center (CCHMC) and the estate of the late Dr. Hector Wong hold patents for the pediatric sepsis biomarker risk model (PERSEVERE) for risk stratification of pediatric sepsis patients and gene expressionbased adaptive endotypes. Dr. Atreya received funding from the National Institute of Child Health and Human Development (NICHD) (R21HD096402) and the National Institute of General Medical Sciences, he disclosed he holds patents for the pediatric sepsis biomarker risk model (PERSEVERE) for risk stratification of pediatric sepsis patients and gene expression-based adaptive endotypes. Drs. Atreya, Bennett, Faustino, Lufti, and Sanchez-Pinto received support for article research from the National Institutes of Health (NIH). Dr. Bennett's institution received funding from the NICHD, the National Center for Advancing Translational Sciences, and the National Heart, Lung, and Blood Institute. Drs. Faustino and Sanchez-Pinto's institutions received funding from the NIH. Dr. Cvijanovich's institution received funding from CCHMC, Boston Children's Hospital, the Centers for Disease Control, and Nationwide Children's Hospital. Dr. Thomas received funding from Bayer AG. The remaining authors have disclosed that they do not have any potential conflicts of interest. This work was supported by grant R21HD096402 from the Eunice Kennedy Shriver National Institute for Child Health and Human Development (Dr. Sanchez-Pinto). Drs. Atreya and Sanchez-Pinto received funding from R21GM151703. Cincinnati Children\u2019s Hospital Medical Center (CCHMC) and the estate of the late Dr. Hector Wong hold patents for the pediatric sepsis biomarker risk model (PERSEVERE) for risk stratification of pediatric sepsis patients and gene expression-based adaptive endotypes. Dr. Atreya received funding from the National Institute of Child Health and Human Development (NICHD) (R21HD096402) and the National Institute of General Medical Sciences, he disclosed he holds patents for the pediatric sepsis biomarker risk model (PERSEVERE) for risk stratification of pediatric sepsis patients and gene expression-based adaptive endotypes. Drs. Atreya, Bennett, Faustino, Lufti, and Sanchez-Pinto received support for article research from the National Institutes of Health (NIH). Dr. Bennett\u2019s institution received funding from the NICHD, the National Center for Advancing Translational Sciences, and the National Heart, Lung, and Blood Institute. Drs. Faustino and Sanchez-Pinto\u2019s institutions received funding from the NIH. Dr. Cvijanovich\u2019s institution received funding from CCHMC, Boston Children\u2019s Hospital, the Centers for Disease Control, and Nationwide Children\u2019s Hospital. Dr. Thomas received funding from Bayer AG. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Keywords
- biomarkers
- critical care
- endothelial dysfunction
- multiple organ dysfunction syndrome
- precision medicine
- sepsis
- systemic inflammation
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Critical Care and Intensive Care Medicine